DALLAS, May 11, 2026
Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, where the company will showcase new clinical and manufacturing findings supporting its investigational MCO-010 optogenetic therapy platform for retinal degenerative diseases. The presentations will focus on expanding evidence behind the company’s mutation-agnostic vision restoration approach, including new observations related to bilateral functional improvement, color vision restoration, and manufacturing advances supporting large-scale gene therapy development.
Nanoscope’s lead program, MCO-010, is currently the most advanced therapy within the company’s proprietary multi-characteristic opsin (MCO) platform and is designed as a one-time intravitreal gene therapy intended to restore functional vision in patients with severe retinal degeneration, including retinitis pigmentosa (RP) and Stargardt disease (SD). The company stated that MCO-010 remains the first and only mutation-agnostic optogenetic therapy to demonstrate vision restoration in advanced RP patients through a single in-office injection without requiring genetic testing or invasive surgical procedures.
Clinical Presentations Highlight Bilateral and Color Vision Improvements
At ASGCT 2026, Nanoscope will present expanded clinical and nonclinical findings demonstrating the potential therapeutic effects of MCO-010 across multiple visual functions. One of the company’s featured podium presentations will focus on bilateral functional improvement following unilateral administration of MCO-010, an observation that could significantly strengthen the therapeutic potential of the platform. The presentation will include findings from both nonclinical models and clinical studies involving patients with retinitis pigmentosa and Stargardt disease.
Researchers observed functional vision improvements extending beyond the treated eye, suggesting possible broader neurological or retinal network effects associated with the therapy. Another major presentation will explore the mechanism and clinical evidence supporting color discrimination improvements in patients receiving MCO-010. According to Nanoscope, treated RP and Stargardt disease patients demonstrated encouraging signs of restored color sensitivity following therapy administration. The company believes these findings further support the potential of its optogenetic platform to restore meaningful real-world visual function rather than limited light perception alone. Executives emphasized that these observations reinforce confidence in MCO-010 as the company continues advancing toward completion of its U.S. Biologics License Application (BLA) submission.
Advertisement
Mutation-Agnostic Optogenetic Platform Targets Broad Retinal Disease Population
Nanoscope’s MCO platform was designed to address major limitations associated with conventional inherited retinal disease therapies that typically target only specific genetic mutations. The company’s disease-agnostic optogenetic approach works by converting surviving bipolar retinal cells into light-sensitive cells capable of restoring visual signaling after photoreceptor degeneration has occurred. Because the therapy does not depend on specific genetic mutations, it may potentially serve a much broader patient population suffering from retinal degenerative diseases. The treatment is delivered through a one-time standard intravitreal injection performed in-office without the need for invasive retinal surgery or repeated dosing.
The company stated that this simplified administration model could improve accessibility and integration into standard retinal care workflows. Nanoscope has already reported positive results from its RESTORE Phase 2b/3 clinical trial evaluating MCO-010 in retinitis pigmentosa patients and has initiated a rolling BLA submission to the U.S. FDA. The therapy has also demonstrated promising clinical activity in the STARLIGHT Phase 2 study involving Stargardt disease patients, with plans to initiate a Phase 3 registrational study during 2026.
Manufacturing and Regulatory Insights Support Gene Therapy Expansion
In addition to clinical efficacy presentations, Nanoscope will also present research focused on AAV manufacturing quality control and regulatory considerations surrounding gene therapy commercialization. Poster presentations at ASGCT 2026 will address orthogonal quantitation methods for detecting replication-competent AAV during manufacturing as well as broader chemistry, manufacturing, and controls (CMC) challenges observed across gene therapy regulatory submissions and FDA complete response letters.
These manufacturing discussions highlight the growing importance of scalable production quality and regulatory compliance within the rapidly expanding gene therapy sector. Nanoscope’s broader pipeline also continues expanding into additional retinal degenerative conditions, including planned clinical development in geographic atrophy (GA) and Leber congenital amaurosis (LCA). The company’s programs have already received multiple regulatory designations globally, including FDA Fast Track, Orphan Drug, and RMAT designations, reflecting the significant unmet medical need associated with inherited retinal disorders and blindness-related diseases.
Source: Nanoscope Therapeutics press release
